Learning Objectives:
  1. Understand the anti IL-23 mechanism drug mechanism.
  2. Understand efficacy data and dosing for risankizumab in ulcerative colitis.
  3. Understand efficacy data for guselkumab in ulcerative colitis.
Session date: 
10/01/2024 - 4:30pm to 5:30pm CDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or create an account to proceed.
Speaker Name: 
Dr. Sushila Dalal